AZN vs INVA
AZN: AstraZeneca is a global, science-led biopharmaceutical company focused on transforming patient outcomes in oncology, rare diseases, and chronic conditions through a robust and diverse R&D pipeline. INVA: Innoviva is a diversified pharmaceutical holding company managing a portfolio of respiratory royalty assets and specialty medicine operations.
Side-by-side fundamentals
| Metric | AZN | INVA | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $168.82 | $21.28 | |
| Market cap | $254.2B | $1.5B | |
| P/E as of 2026-10-20 | n/a | 4.94 (earnings are mostly non-operating: 61% of trailing pre-tax income, to 2026-06-30) | |
| Net margin FY2025, SEC XBRL | +17.4% | +65.9% | INVA higher |
| Gross margin FY2025, SEC XBRL | +81.9% | +74.8% | AZN higher |
| Operating margin FY2025, SEC XBRL | +23.4% | +39.8% | INVA higher |
| ROE FY2025, SEC XBRL | +21.0% | +23.1% | INVA higher |
| ROA FY2025, SEC XBRL | +9.0% | +16.6% | INVA higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.21 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +8.6% | +14.7% | INVA higher |
| Revenue CAGR (3y) SEC XBRL | +9.8% | +7.5% | AZN higher |
| Dividend yield as of 2026-09-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.34 | 0.14 | |
| 1-year return as of 2026-10-20 close | +0.6% | +23.6% | INVA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.